INTRODUCTION
The prevalence of diabetes is increasing worldwide [1] . Good glycemic control is an important goal of diabetes treatment to prevent and/or delay long-term microvascular complications [2, 3] . Current guidelines from the International Diabetes Federation (IDF) and joint American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) recommend the glycated hemoglobin (HbA 1c ) target of \7.0%, with some individualization according to age [4] [5] [6] . For example, the IDF recommends the HbA 1c target of 7.0-7.5% for people with type 2 diabetes aged 70 years or older [4] , and California Healthcare Foundation/American Geriatrics Society Panel guidelines recommend the target of \7.0% for people with diabetes aged 65 years or older [7] .
The ADA/EASD position statement [5] and IDF guidelines [4] Randomized, parallel studies have shown that insulin detemir, given as add-on therapy to oral glucose-lowering drugs (OGLDs) in people with uncontrolled type 2 diabetes, is associated with reduced risk of hypoglycemia compared with neutral protamine Hagedorn (NPH) [11, 12] . Furthermore, large observational studies in people with type 2 diabetes have shown that insulin detemir results in significantly reduced HbA 1c , fasting plasma glucose (FPG) and withinpatient FPG variability [13, 14] , with low rates of adverse events and hypoglycemia, and no weight gain [13, 14] .
A 1 chieve was an international noninterventional study evaluating the clinical safety and effectiveness of insulin analogs in people with type 2 diabetes in everyday clinical practice [15, 16] . The study demonstrated the safety and effectiveness of these insulin analog therapies [15] , and significant improvements in health-related quality of life (HRQoL) [16] . This sub-analysis of data from A 1 chieve evaluated the clinical safety and effectiveness of insulin detemir in three age-groups. Additionally, the data were analyzed by pre-study insulin experience. This sub-analysis included patients starting or switching to treatment with insulin detemir alone or in combination with OGLDs. To reflect routine clinical practice as much as possible, inclusion and exclusion criteria were minimal. Further details on inclusion and exclusion criteria, and study design were previously published [15] . Insulin detemir was used according to the label approved by the regulatory authority.
MATERIALS AND METHODS

Assessments and Outcome Measures
Assessment sessions were defined as baseline, interim [approximately 12 weeks from baseline (results not reported here)] and study end (approximately 24 weeks from baseline). The primary objective was to assess the safety profile of insulin detemir by evaluating the incidence of serious adverse drug reactions (SADRs), including major hypoglycemia events. An additional safety assessment was change in the number of hypoglycemia events between baseline and 24 weeks, which was based on patient recall of events within the last 4 weeks prior to the study visit.
A hypoglycemia event was defined as an event with symptoms of hypoglycemia that resolved with oral carbohydrate intake, glucagon or intravenous glucose, or any symptomatic or asymptomatic event where plasma glucose was \3.1 mmol/l or 56 mg/dl.
Nocturnal hypoglycemia events were defined as individualized symptomatic events consistent with hypoglycemia, occurring during sleep, after the evening insulin injection and before getting up in the morning; and if relevant, before morning determination of FPG and the morning insulin injection. Major hypoglycemia events were defined as events with severe central nervous system symptoms consistent with hypoglycemia in which the patient was unable to self-treat and had one of the following characteristics: plasma glucose \3.1 mmol/l or 56 mg/dl, or reversal of symptoms after either food intake, glucagon or intravenous glucose administration.
The secondary objective was to investigate the clinical effectiveness of insulin detemir. Carolina, USA). All statistical tests were twosided, using a pre-specified 5% significance level. 
RESULTS
Study Participants
Baseline characteristics of the participants are shown in Table 1 were insulin-naïve before the study.
Safety Measures
Insulin Dose
In all three age-groups, mean total insulin dose appeared to increase slightly between baseline (when patients started or switched to insulin detemir) and 24 weeks ( Table 2 ).
All Hypoglycemia Events
At 24 weeks, the proportion of participants experiencing hypoglycemia in the entire cohort and in insulin-experienced patients was significantly reduced from baseline in all agegroups (Table 3 ). In insulin-naïve patients, the proportion experiencing hypoglycemia was significantly reduced from baseline in the B40 years age-group and significantly increased in the [65 years age-group at 24 weeks (Table 3 ). There was no significant change between baseline and 24 weeks in the proportion of participants experiencing hypoglycemia in the [40-65 years age-group (Table 3) . At both baseline and week 24, there was no indication in any age-group that the proportion experiencing hypoglycemia was higher in participants taking sulfonylureas compared with those who were not (Table 3) .
Major Hypoglycemia Events
In the entire cohort and in insulin-experienced patients, the proportion of participants experiencing major hypoglycemia was significantly reduced at 24 weeks relative to baseline (Table 3 ). In insulin-naïve patients, the proportion of patients experiencing major hypoglycemia was significantly reduced from baseline in the [40-65 and [65 years agegroups at 24 weeks, and no major hypoglycemia was reported in the B40 years age-group at 24 weeks (Table 3) .
Nocturnal Hypoglycemia Events
The proportion of participants experiencing nocturnal hypoglycemia was significantly lower at 24 weeks versus baseline in all three age-groups in the entire cohort and in insulinexperienced patients (Table 3 ). In insulin-naïve patients, the proportion experiencing nocturnal hypoglycemia was significantly reduced from baseline in the B40 years age-group and significantly increased in the [65 years agegroup, with no significant change in the [40-65 years age-group (Table 3) .
SADRs
There were seven reports of SADRs in the 15,241 people with type 2 diabetes receiving insulin detemir (±OGLDs). None of these were in the B40 years age-group. Six SADRs were reported in the[40-65 years age-group (three episodes of hyperglycemia and three episodes of hypoglycemia). Of these, two episodes of Due to the observational nature of this study not all measures were reported or collected * p\0.05 for proportion of patients with at least one event at 24 weeks relative to baseline ** p\0.01 for proportion of patients with at least one event at 24 weeks relative to baseline *** p\0.001 for proportion of patients with at least one event at 24 weeks relative to baseline a n for each cohort same as for hypoglycemia (overall) data hyperglycemia and two episodes of hypoglycemia were probably related to insulin detemir treatment (with good reasons and sufficient documentation to assume a causal relationship), and one episode of hyperglycemia and one episode of hypoglycemia were possibly related (a causal relationship was conceivable and could not be dismissed). One SADR (an episode of hypoglycemia) was reported in the [65 years age-group, which was probably related to insulin detemir treatment.
Body Weight
In the B40 and [40-65 years age-groups, body weight was significantly reduced at 24 weeks; in the [65 years age-group, body weight was significantly increased (Table 4 ). In insulinexperienced patients, significant reduction in body weight was observed in the [40-65 and [65 years age-groups, and there was no significant change in the B40 years age-group (Table 4 ). In insulin-naïve patients, significant reduction in body weight was observed in the B40 and [40-65 years age-groups, and the [65 years age-group showed significant weight gain (Table 4) .
Effectiveness Measures
Glycemic Measures
Significant reductions in HbA 1c were achieved in all age-groups and in insulin-experienced and insulin-naïve patients at 24 weeks (Table 4 ; Fig. 1 ). The percentage of participants with HbA 1c \7.0% appeared to increase between baseline and 24 weeks in all three age-groups in insulin-experienced and insulin-naïve ( between baseline and 24 weeks for all agegroups and in both insulin-experienced and insulin-naïve patients (Table 4) . PPG levels were also significantly lowered in all age-groups at 24 weeks (Table 4 ). In both insulin-experienced and insulin-naïve patients, all age-groups showed significant improvements in FPG and PPG at 24 weeks (Table 4) .
HRQoL
All age-groups, whether insulin-experienced or insulin-naïve, had significantly improved UK VAS scores at 24 weeks (Table 4) .
DISCUSSION
This sub-analysis of the A 1 chieve study reports the results for people with poorly controlled type 2 diabetes of different age-groups who switched to, or started, insulin therapy with insulin detemir. The data showed that 24-week treatment with insulin detemir (±OGLDs) in routine clinical practice resulted in improved glycemic control for all age-groups, in both insulin-experienced and insulin-naïve patients.
HbA 1c levels were significantly reduced in all age-groups overall and in insulin-experienced and insulin-naïve patients after 24-week treatment with insulin detemir. FPG and PPG levels were significantly improved across all agegroups and in insulin-naïve or insulinexperienced patients.
Insulin detemir was well tolerated in all agegroups. Not surprisingly, baseline hypoglycemia appeared to be more frequent in insulin- Table 4 continued The observed increase in HRQoL in all agegroups may reflect the overall improvements in incidence of hypoglycemia reported for insulin detemir treatment [22, 23] . It is surprising that overall hypoglycemia and nocturnal hypoglycemia were significantly reduced at 24 weeks compared with baseline in insulinnaïve patients in the B40 years age-group, while there was no change in the [40-65 years agegroup and a significant increase in the[65 years age-group. There is no clear explanation for the reduced hypoglycemia in the B40 years agegroup, but it could be related to pre-study OGLD use; for example, sulfonylureas are associated with an increased risk of hypoglycemia [24] . There was a reduction in sulfonylurea use between baseline and week 24 in this age-group that could potentially have contributed to a lower rate of hypoglycemia. However, a similar decrease in sulfonylurea use was observed in the other age-groups and there was no evidence for a higher rate of hypoglycemia in participants taking sulfonylureas compared with those who were not. Therefore, an alternative explanation may be needed.
Interestingly, in patients aged [65 years, those switching to insulin detemir had significant weight loss while those starting insulin detemir had significant weight gain at 24 weeks. The weight changes were significant but small, and therefore, may not be clinically important.
Furthermore, this difference between insulin-naïve and insulin-experienced patients was not observed in the other age- Fig. 1 Effectiveness results by age-group and pre-study insulin experience Consistent with the results of other studies [13, 14] and the overall A 1 chieve population [15] , the results of this sub-analysis suggest that insulin detemir is well tolerated, and improves glycemic control and HRQoL in most groups of people with poorly controlled type 2 diabetes versus their previous insulin regimen.
Improvements in glycemic control and HRQoL were observed across a wide range of agegroups, and both in patients initiating insulin therapy with insulin detemir and those switching from other insulin regimens. The proportion of participants reporting hypoglycemia events was reduced in all agegroups in the entire cohort and in insulinexperienced patients, and the reduced proportion of elderly people with type 2 diabetes reporting major hypoglycemia is particularly important.
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